Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis

A 42-year-old man with relapsing-remitting MS developed severe reversible left ventricular dysfunction 24-36 hours after ocrelizumab infusion, with comprehensive cardiac investigation excluding ischemic or infectious causes. This case raises awareness of a potential rare cardiotoxic effect of ocrelizumab and underscores the need for cardiac monitoring in MS patients receiving this therapy.